Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 6, 2016, Pages 554-567

  Bek, S ^a   Nielsen, J V ^a   Bojesen, A B ^b   Franke, A ^c   Bank, S ^a   Vogel, U ^d   Andersen, V ^a,e  

^a Hospital of Southern Jutland   (Denmark)

^b Research Unit of Mental Health   (Denmark)

^c UNIVERSITY OF KIEL   (Germany)

^d NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; IMMUNOGLOBULIN G; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

BINDING AFFINITY; CELL MEDIATED CYTOTOXICITY; CROHN DISEASE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; FCGR3A GENE; GENE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; IFNG GENE; IL1B GENE; IL6 GENE; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); TLR2 GENE; TLR4 GENE; TLR9 GENE; TNFRSF1A GENE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 84981164619     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13736     Document Type: Review

References (47)

1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307–17.
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46–54.
3. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Investig 2007; 117: 514–21.
4. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011; 474: 298–306.
5. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 2013; 62: 1653–64.
6. MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 2011; 140: 1768–75.
7. Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011; 140: 1729–37.
8. Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 2013; 369: 754–62.
9. Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol 2014; 20: 64–77.
10. Dignass A, van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28–62.
11. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991–1030.
12. Mastrandrea LD. An overview of organ-specific autoimmune diseases including immunotherapy. Immunol Invest 2015; 44: 803–16.
13. http://permed2020.eu/. http://permed2020.eu/ 2015.
14. Gerich ME, McGovern DP. Towards personalized care in IBD. Nat Rev Gastroenterol Hepatol 2014; 11: 287–99.
15. Siegel CA, Melmed GY. Predicting response to Anti-TNF Agents for the treatment of crohn's disease. Therap Adv Gastroenterol 2009; 2: 245–51.
16. Siegel CA, Horton H, Siegel LS, et al. A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables. Aliment Pharmacol Ther 2016; 43: 262–71.
17. Ding NS, Hart A, de Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease – algorithm for practical management. Aliment Pharmacol Ther 2016; 43: 30–51.
18. Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W. Review article: the role of anti-TNF in the management of ulcerative colitis – past, present and future. Aliment Pharmacol Ther 2013; 37: 855–66.
19. Andersen V, Holst R, Vogel U. Systematic review: diet-gene interactions and the risk of colorectal cancer. Aliment Pharmacol Ther 2013; 37: 383–91.
20. Andersen V, Vogel U. Systematic review: interactions between aspirin, and other nonsteroidal anti-inflammatory drugs, and polymorphisms in relation to colorectal cancer. Aliment Pharmacol Ther 2014; 40: 147–59.
21. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 2008; 359: 789–99.
22. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105–9.
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS.Med 2009; 6: e1000097.
24. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–48.
25. Bank S, Andersen PS, Burisch J, et al. Associations between functional polymorphisms in the NFkappaB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J 2014; 14: 526–34.
26. Mascheretti S, Hampe J, Croucher PJ, et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002; 12: 509–15.
27. Mascheretti S, Hampe J, Kuhbacher T, et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002; 2: 127–36.
28. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 818–24.
29. Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004; 19: 511–9.
30. Pierik M, Vermeire S, Steen KV, et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004; 20: 303–10.
31. Willot S, Vermeire S, Ohresser M, et al. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet Genomics 2006; 16: 37–42.
32. Dideberg V, Louis E, Farnir F, et al. Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet Genomics 2006; 16: 369–73.
33. Dideberg V, Theatre E, Farnir F, et al. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet Genomics 2006; 16: 727–34.
34. Louis EJ, Watier HE, Schreiber S, et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 2006; 16: 911–4.
35. Moroi R, Endo K, Kinouchi Y, et al. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics 2013; 65: 265–71.
36. Medrano LM, Taxonera C, Marquez A, et al. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab. Hum Immunol 2014; 75: 71–5.
37. Koder S, Repnik K, Ferkolj I, et al. Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients. Pharmacogenomics 2015; 16: 191–204.
38. Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002; 123: 106–11.
39. Hlavaty T, Pierik M, Henckaerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 2005; 22: 613–26.
40. Hlavaty T, Persoons P, Vermeire S, et al. Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease. Inflamm Bowel Dis 2006; 12: 199–204.
41. Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet 2016; 387: 156–67.
42. Lee YH, Bae SC, Song GG. Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis. Rheumatol Int 2014; 34: 1409–15.
43. Zhang X, Zhang D, Jia H, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 2015; 21: 895–905.
44. Andersen V, Vogel U. Interactions between meat intake and genetic variation in relation to colorectal cancer. Genes Nutr 2015; 10: 448.
45. Andersen V, Ernst A, Christensen J, et al. The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case-control study. BMC Med Genet 2010; 11: 82.
46. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119–24.
47. Goyette P, Boucher G, Mallon D, et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet 2015; 47: 172–9.